Reduction of IOP with latanoprost.
Hoste
A M
AM
D000287:Administration, Topical; D000818:Animals; D001783:Blood Flow Velocity / Q000187:drug effects / Q000502:physiology; D015232:Dinoprostone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005901:Glaucoma / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D009880:Ophthalmic Artery / Q000187:drug effects / Q000503:physiopathology; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*; D014661:Vasoconstriction / Q000187:drug effects
D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D015232:Dinoprostone